Assessment of Psilocybin Therapy for Patients With Cancer and Major Depression Disorder
Manish Agrawal, Ezekiel Emanuel, Brian D. Richards, William A. Richards, Kim Roddy, Paul Thambi
JAMA Oncology April 13, 2023 DOI: 10.1001/jamaoncol.2023.0351 via OpenAlex
Summary
AI-generated from the abstractIn a nonrandomized controlled trial, psilocybin was administered to groups of patients with cancer who also had major depressive disorder, using a one-to-one therapist-to-patient ratio. The aim was to develop a scalable, rapidly effective depression treatment. The trial suggests that this approach may offer a feasible model for delivering psilocybin therapy to larger numbers of patients while maintaining therapeutic support.
Study at a glance
| Characteristics | Nonrandomized controlled trial Peer reviewed |
|---|---|
| Population | Patients with cancer diagnosed with major depressive disorder |
| Intervention | Psilocybin |
| Topics | Depression Psilocybin |
| Keywords | Depression economics Psychiatry Cancer therapy |
| Citations | 48 |
| Key finding | Administering psilocybin with a one-to-one therapist-to-patient ratio to groups of patients with cancer and major depressive disorder may provide a scalable, rapidly effective depression treatment. |
Abstract
This nonrandomized controlled trial used a 1-to-1 therapist-to-patient ratio to administer psilocybin to groups of patients with cancer who were diagnosed with major depression disorder to create a scalable, rapidly effective depression treatment.